Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

SVB Leerink cuts Benefytt Technologies to MP; PT up to $31 from $27.50

SVB Leerink downgraded Benefytt Technologies (NASDAQ:BFYT) to “market perform” from “outperform” but raised its price target to $31 from $27.50 after Madison Dearborn Partners agreed to acquire Benefytt for $31 a share...

July 14, 2020

Markets

BTIG cuts Gritstone Oncology PT to $17 from $31

BTIG reduced its price target for Gritstone Oncology (NASDAQ:GRTS) to $17 from $31, citing interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen...

July 14, 2020

Developments

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), began enrolling patients in its Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is an orally...

July 13, 2020

Developments

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) treated the first patient in its Phase 3 study evaluating INOpulse, a pulsed nitric oxide system, for the treatment of COVID-19. The study will enroll up to 500 patients requiring...

July 13, 2020

Developments

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

The FDA has issued an emergency use authorization for electroCore’s (NASDAQ:ECOR) gammaCore Sapphire CV non-invasive vagus nerve stimulation (nVNS) to treat adult patients with known or suspected COVID-19. The FDA has...

July 13, 2020

Developments

Adverum randomizes first patient in Phase 2 diabetic macular edema study

Adverum Biotechnologies (NASDAQ:ADVM) randomized the first patient in its INFINITY clinical trial evaluating ADVM-022 for the treatment of diabetic macular edema (DME). ADVM-022 is a one-time intravitreal gene therapy...

July 13, 2020

Markets

BTIG ups Vapotherm PT to $53 from $32

BTIG raised its price target for Vapotherm (NASDAQ:VAPO) to $53 from $32, citing a higher compound annual growth rate for revenue after a proprietary survey of U.S. hospitals that purchased the company’s Precision Flow...

July 13, 2020

Developments

Tonix Pharmaceuticals meets target enrollment in Phase 3 fibromyalgia study

Tonix Pharmaceuticals (NASDAQ:TNXP) met its target enrollment of 470 patients in its Phase 3 study of TNX-102 SL for the management of fibromyalgia. TNX-102 SL is a non-opioid analgesic, administered daily at bedtime...

July 10, 2020

Developments Markets

Mayo Clinic listed on TULSA center locator page, indicating Profound Medical’s first sale to a teaching hospital

The Mayo Clinic has just been listed as a new TULSA-PRO site, representing the first sale of the system to a teaching hospital by the technology’s developer, Profound Medical Profound Medical (TSX:PRN; NASDAQ:PROF)...

July 9, 2020

Developments

FDA approves Osmotica Pharma’s Upneeq for blepharoptosis

The FDA approved Osmotica Pharmaceuticals’ (NASDAQ:OSMT) Upneeq for the treatment of acquired blepharoptosis, an abnormal drooping of the upper eyelid that can limit field of vision. Acquired blepharoptosis is often...

July 9, 2020

Executive Moves

Elemer Piros rejoins Roth healthcare research team

Elemer Piros Elemer Piros has rejoined the healthcare research team at Roth Capital Partners as managing director, senior research analyst covering biotechnology. His research coverage is expected to include small...

July 9, 2020

Developments

Crinetics Pharma’s paltusotine gets FDA orphan drug designation for acromegaly

The FDA granted Crinetics Pharmaceuticals’ (NASDAQ:CRNX) paltusotine orphan drug designation for the treatment of acromegaly, a disease usually caused by a benign growth hormone-secreting tumor in the brain’s pituitary...

July 8, 2020

Subscribe